What's Happening?
Eli Lilly has received FDA approval for a new maintenance dosing regimen for its eczema drug, Ebglyss (lebrikizumab). The drug, which targets the IL-13 pathway, can now be administered every eight weeks following an initial induction period of bi-weekly
injections. This new dosing schedule offers a competitive advantage over other IL-13-targeting drugs like Sanofi/Regeneron's Dupixent and LEO Pharma's Adbry, which require more frequent dosing. The approval is based on the Q8W Adjoin extension trial, which demonstrated that the efficacy of Ebglyss remains consistent whether dosed every four or eight weeks. Ebglyss was first approved in Europe in 2023 and subsequently in the US, Japan, and Canada in 2024. It generated $408 million in revenue for Lilly in 2025. The drug is currently approved for use in adults and children over 12, with potential label expansion to include younger patients.
Why It's Important?
The FDA's approval of a less frequent dosing regimen for Ebglyss could significantly impact the treatment landscape for moderate-to-severe atopic dermatitis. By reducing the frequency of injections to just six times a year, Ebglyss offers a more convenient option for patients, potentially improving adherence and quality of life. This could lead to increased market share for Lilly, as the drug's dosing schedule is more favorable compared to its competitors. Additionally, the ability to avoid the use of topical therapies like corticosteroids and emollients further enhances its appeal. The approval could translate into a $6 billion peak sales opportunity for Lilly and its European partner, Almirall.
What's Next?
Following this approval, Eli Lilly may focus on expanding the label of Ebglyss to include younger patients, as indicated by recent clinical trial data. This could open up a new demographic and further increase the drug's market potential. Additionally, the company will likely continue to monitor the drug's performance in the market and gather real-world data to support its efficacy and safety profile. Competitors may respond by seeking similar approvals for less frequent dosing or by enhancing their own treatment offerings.
